Literature DB >> 20829400

Sepsis with prolonged hypotension due to Moraxella osloensis in a non-immunocompromised child.

Jennifer Dien Bard1, Michael Lewinski2,1, Paula H Summanen3, Jaime G Deville4.   

Abstract

We report a case of septicaemia with prolonged, refractory hypotension related to Moraxella osloensis isolated in a non-immunocompromised paediatric patient.

Entities:  

Mesh：

Year:  2010        PMID： 20829400     DOI： 10.1099/jmm.0.016378-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN： 0022-2615            Impact factor:   2.472


  6 in total

1.  The first Korean case of Moraxella osloensis bacteremia in a patient with acute myeloid leukemia.

Authors:  Ji Yeon Sung; Sung Kuk Hong; Eui-Chong Kim
Journal:  Ann Lab Med       Date:  2014-04-08       Impact factor: 3.464

2.  Endocarditis Caused by Gram-Negative Moraxella osloensis in an Immunocompetent Patient: First Case Report in Latin America.

Authors:  Patricia Fraga Paiva; Carolina Fraga Paiva; Emanoel Guimarães Paiva; Gisele Maria Campos Fabri; José Fabri Junior
Journal:  Case Rep Cardiol       Date:  2018-06-06

3.  Moraxella osloensis: an unusual cause of central venous catheter infection in a cancer patient.

Authors:  Yoshiro Hadano; Kenta Ito; Jun Suzuki; Ichiro Kawamura; Hanako Kurai; Kiyofumi Ohkusu
Journal:  Int J Gen Med       Date:  2012-10-17

4.  An unusual osteomyelitis caused by Moraxella osloensis: A case report.

Authors:  Nidal J Alkhatib; Manaf H Younis; Ahmad S Alobaidi; Nebal M Shaath
Journal:  Int J Surg Case Rep       Date:  2017-10-18

5.  [Moraxella osloensis emerging infection. Visiting to genital infection].

Authors:  C Gómez-Camarasa; J Fernández-Parra; J M Navarro-Marí; J Gutiérrez-Fernández
Journal:  Rev Esp Quimioter       Date:  2018-04-02       Impact factor: 1.553

Review 6.  Bacteremia due to Moraxella osloensis: a case report and literature review.

Authors:  Yuta Maruyama; Tomonari Shigemura; Koki Aoyama; Noriyuki Nagano; Yozo Nakazawa
Journal:  Braz J Infect Dis       Date:  2018-02-02       Impact factor: 3.257
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.